Leadership and the left shift: advancing proactive and preventive healthcare

Prevention must be reframed, not as a cost-saving measure, but as a value-creating strategy that reverses poor health outcomes, reduces acute care demand, builds healthier communities, and supports economic growth.

Medicines, too, must be recognised not only as therapeutic tools but as enablers of prevention. When integrated into early intervention strategies, they can reduce disease progression, improve quality of life, and support a sustainable healthcare system. This shift requires coordinated investment, policy reform and a new narrative – one that positions medicines as part of the prevention toolkit.

Crucially, we cannot improve what we don’t measure. Establishing meaningful metrics to track the impact of preventive care is essential to validate success and inform data-driven decisions that continuously improve patient pathways. These metrics might include reductions in emergency hospital admissions, increased uptake of screening and vaccination programmes, improvements in patient-reported outcomes, and data on health inequalities across different population groups. Metrics should guide investment, inform policy, and validate success – not just in clinical terms, but in human ones.

Reaching further through partnerships that deliver

At Boehringer Ingelheim, we are proud to be part of several pioneering collaborations that demonstrate how industry and the NHS can together drive systemic change by co-creating scalable, equitable models of care.

In collaboration with the North East and North Cumbria Integrated Care Board, through Health Innovation North East and North Cumbria, and the Hampshire and Isle of Wight Integrated Care System, we are jointly leading the SPOT CKD (Screening, Prevention, Outreach and Treatment for Health Equity) initiative. This programme aims to improve the early detection and management of chronic kidney disease, particularly in underserved communities who cannot, or do not, access the healthcare they need. 

Aligned with the NHS England Renal Transformation Programme, the SPOT CKD initiative embeds a proactive ‘target, test and treat’ approach into routine practice. By closing testing gaps, monitoring at-risk individuals and delivering personalised treatment, the initiative supports the NHS prevention agenda and ensures patients receive timely, equitable and sustainable care.

Additionally, we are streamlining diagnostic and treatment pathways for rare lung cancers through our partnership with The Christie NHS Foundation Trust. This collaboration aims to standardise processes, accelerate diagnosis, and tackle inequalities in access and outcomes to targeted therapies. By contributing data to NHS England, this initiative also supports national prevention efforts and the development of expert-led guidelines, helping to shape the future of cancer care.

These partnerships are not just about improving today’s services, they are about building a more resilient, inclusive, and sustainable healthcare system for tomorrow.

The road ahead

As we look to the future, partnerships like these between industry, public health organisations, communities and patients will be essential in delivering the transformative change the NHS needs. 

Delivering the left shift is not about incremental change, it’s about systemic redesign. It demands leadership that is pragmatic, collaborative and relentlessly focused on outcomes. We must move beyond pilots and pledges to build a healthcare system that is inclusive by design, digital by default, and preventive by principle.

The future of care is not solely about treating illness, it’s about enabling health. Continued leadership and collaboration will be key to breaking down barriers, driving innovation and securing better outcomes for generations to come.

Vani Manja is country managing director and head of human pharma at Boehringer Ingelheim UK and Ireland.